Online citations, reference lists, and bibliographies.
← Back to Search

Liposomes. Opportunities In Drug Delivery.

T. Allen
Published 1997 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Liposomal drug delivery systems markedly alter the biodistribution of their associated drugs by delaying drug clearance, retarding drug metabolism, decreasing the volume of distribution, and shifting the distribution in favour of diseased tissues with increased capillary permeability. This increases the therapeutic indices of the associated drugs, by increasing the drug concentration in solid tumours and regions of infection, and reducing the drug concentration in normal tissues. Three liposomal formulations have been approved for clinical use.
This paper references
Liposomal doxorubicin (Doxil) is active against refractory ovarian cancer
(1996)
10.1016/0005-2736(84)90135-4
Liposomal amphotericin B is toxic to fungal cells but not to mammalian cells.
R. Mehta (1984)
10.1073/PNAS.88.24.11460
Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy.
D. Papahadjopoulos (1991)
Initial clinical (phase I) trial of TLC D-99 (doxorubicin encapsulated in liposomes).
J. W. Cowens (1993)
10.1016/0925-4439(92)90010-K
Enhanced localization of liposomes with prolonged blood circulation time in infected lung tissue.
I. A. Bakker-Woudenberg (1992)
10.1016/0169-409X(94)90018-3
Clinical application of phospholipid liposomes containing macrophage activators for therapy of cancer metastasis
I. Fidler (1994)
10.1016/0005-2736(91)90162-2
Sterically stabilized liposomes: a hypothesis on the molecular origin of the extended circulation times.
D. Lasic (1991)
10.1093/JAC/33.5.907
Clinical use of liposomal and lipid-complexed amphotericin B.
S. de Marie (1994)
Uster p . et al . Tumour uptake of doxorubicin in polyethylene glycol - coated liposomes and therapeutic effect against a xenografted human pancreatic carcinoma
D Donovan (1997)
10.1021/BI00281A024
Differences in the interaction of the polyene antibiotic amphotericin B with cholesterol- or ergosterol-containing phospholipid vesicles. A circular dichroism and permeability study.
A. Vertut-Croquin (1983)
10.1016/S0169-409X(96)00402-4
Therapeutic opportunities for targeted liposomal drug delivery
T. Allen (1996)
10.1002/JPS.2600820617
Chromatographic analysis and pharmacokinetics of liposome-encapsulated doxorubicin in non-small-cell lung cancer patients.
L. Embree (1993)
10.3109/08982109209010216
Complement-Dependent Phagocytosis of Liposomes: Suppression by “Stealth” Lipids
C. Alving (1992)
10.1038/bjc.1996.193
Efficacy and safety of Stealth liposomal doxorubicin in AIDS-related Kaposi's sarcoma. The International SL-DOX Study Group.
F. D. Goebel (1996)
10.1038/bjc.1997.84
Tumour uptake of doxorubicin in polyethylene glycol-coated liposomes and therapeutic effect against a xenografted human pancreatic carcinoma.
J. Vaage (1997)
Hainsworth 1 . leffers S . et al . Liposomal doxorubicin ( Doxil ) is active against refractory ovarian cancer
F Muggia (1996)
Pharmacokinetics of liposomal amphotericin B (AmBisome) versus other lipid-based formulations.
V. Heinemann (1994)
Goebel FD . Efficacy of Dox - SL ( Stealth ® liposomal doxorubicin ) in the treatment of advanced AIDS - related Kaposi ' s sarcoma
Bogner lR
10.1016/S0169-409X(96)00456-5
Stealth® liposomes: from theory to product
Boris Cˇeh (1997)
10.1097/00003246-199601000-00005
Liposomal prostaglandin E1 in acute respiratory distress syndrome: a placebo-controlled, randomized, double-blind, multicenter clinical trial.
E. Abraham (1996)
10.1016/S0959-8049(97)85238-0
Phase II dose-finding trial of CAELYX™ (Stealth® liposomal doxorubicin HCL) in the treatment of advanced breast cancer
M. Ranson (1997)
10.1200/JCO.1995.13.7.1777
Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies.
B. Uziely (1995)
10.1097/00007890-199501150-00009
Liposomal amphotericin B prevents invasive fungal infections in liver transplant recipients. A randomized, placebo-controlled study.
J. Tollemar (1995)
10.1016/0005-2736(91)90337-8
Influence of surface hydrophilicity of liposomes on their interaction with plasma protein and clearance from the circulation: studies with poly(ethylene glycol)-coated vesicles.
J. Senior (1991)
10.1200/JCO.1995.13.4.996
Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin.
P. Gill (1995)
10.1016/0005-2736(86)90105-7
Uptake of adriamycin into large unilamellar vesicles in response to a pH gradient.
L. Mayer (1986)
Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes.
A. Gabizon (1994)
Torchilin VP . et al . Amphipathic polyethylene glycols effectively prolong the circulation time of Iiposomes
AL Klibanov (1990)
10.1016/0169-409X(94)90016-7
The use of glycolipids and hydrophilic polymers in avoiding rapid uptake of liposomes by the mononuclear phagocyte system
T. Allen (1994)
Liposome pharmacokinetics. In: Ostro MJ, editor. Liposomes: from biophysics to therapeutics
KJ Hwang (1987)
Efficacy and safety of Stealth® lipsomal doxorubicin in AIDS-related Kaposi's sarcoma
M Goebel F-D. Goldstein D. Goos (1996)
10.1200/JCO.1997.15.3.987
Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.
F. Muggia (1997)
Preclinical and clinical studies with liposomal vincristine
Mayer LD. Gelmon K. Cullis PRo (1995)
10.1016/0005-2736(92)90084-Y
In vitro cytotoxicity of liposome-encapsulated doxorubicin: dependence on liposome composition and drug release.
A. Horowitz (1992)
10.1007/s002800050591
Preclinical trial of doxorubicin entrapped in sterically stabilized liposomes in dogs with spontaneously arising malignant tumors
D. Vail (1997)
10.1200/JCO.1995.13.4.914
Liposomal-entrapped doxorubicin: an active agent in AIDS-related Kaposi's sarcoma.
M. Harrison (1995)
10.3171/JNS.1995.83.6.1029
Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model: biodistribution and therapeutic efficacy.
T. Siegal (1995)
Fluorescence imaging studies for the disposition of daunorubicin liposomes (DaunoXome) within tumor tissue.
E. Forssen (1996)
10.1016/S0022-2836(65)80093-6
Diffusion of univalent ions across the lamellae of swollen phospholipids.
A. Bangham (1965)
Phase II dose-finding trial of DOX-SL (Stealth® liposomal doxorubicin HCI) in the treatment of advanced breast cancer
Ranson M. O'Bryne K. Carmichael (1996)
Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules.
H. Dvorak (1988)
Efficacy of Dox-SL (Stealth® liposomal doxorubicin) in the treatment of advanced AIDS-related Kaposi's sarcoma
Bogner lR. Goebel F-D (1995)
Liposome pharmacokinetics
KJ Hwang
Abra R . et al . Tissue distribution and therapeutic effect on intravenous free or encapsulated liposomal doxorubicin on human prostate carcinoma xenografts
E Barbera-Guillem (1994)
10.1016/0005-2736(90)90440-Y
Liposomes for the sustained drug release in vivo.
G. Blume (1990)
10.1016/0005-2736(91)90201-I
Pharmacokinetics of stealth versus conventional liposomes: effect of dose.
T. Allen (1991)
10.1002/j.1552-4604.1996.tb04152.x
Doxorubicin Encapsulated in Liposomes Containing Surface‐Bound Polyethylene Glycol: Pharmacokinetics, Tumor Localization, and Safety in Patients with AIDS‐Related Kaposi's Sarcoma
D. Northfelt (1996)
Association of blood proteins with large unilamellar liposomes in vivo. Relation to circulation lifetimes.
A. Chonn (1992)
O ' Bryne K . Carmichael 1 . et al . Phase II dose - finding trial of DOX - SL ( Stealth ® liposomal doxorubicin HCI ) in the treatment of advanced breast cancer
M Ranson (1996)
10.1016/0014-5793(90)81016-H
Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes
A. Klibanov (1990)
Kronawitter U . Rolinski B . et al . Liposomal doxorubicin in the treatment of advanced AIDS - related Kaposi ' s sarcoma
Bogner (1994)
10.1002/cpt197112196
The pharmacokinetics of daunomycin in man
D. Alberts (1971)
10.1073/PNAS.83.8.2699
Immune clearance of liposomes inhibited by an anti-Fc receptor antibody in vivo.
D. Aragnol (1986)
10.5282/UBM/EPUB.8196
Liposomal doxorubicin in the treatment of advanced AIDS-related Kaposi sarcoma.
J. Bogner (1994)
Increased microvascular permeability contributes to preferential accumulation of Stealth liposomes in tumor tissue.
N. Wu (1993)
10.3109/10611869408996815
Sterically stabilized liposomes: physical and biological properties.
M. Woodle (1994)
10.1016/S0163-4453(96)91343-2
Visceral leishmaniasis in HIV infected patients: treatment with high dose liposomal amphotericin B (AmBisome).
R. Russo (1996)
10.1016/0005-2736(94)90003-5
Poly(ethylene glycol) on the liposome surface: on the mechanism of polymer-coated liposome longevity.
V. Torchilin (1994)
Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft.
F. Yuan (1994)
10.1093/INFDIS/168.1.164
Liposomes with prolonged blood circulation and selective localization in Klebsiella pneumoniae-infected lung tissue.
I. A. Bakker-Woudenberg (1993)
10.1016/0304-4165(85)90174-6
Tissue distribution of liposomes exhibiting long half-lives in the circulation after intravenous injection.
J. Senior (1985)
10.1016/0169-409X(95)00029-7
Pharmacokinetics of long-circulating liposomes
T. Allen (1995)
10.1002/1097-0142(19940301)73:5<1478::AID-CNCR2820730526>3.0.CO;2-1
Tissue distribution and therapeutic effect of intravenous free or encapsulated liposomal doxorubicin on human prostate carcinoma xenografts
J. Vaage (1994)
10.1097/00000421-199412000-00009
A Phase II Trial of DaunoXome, Liposome‐ Encapsulated Daunorubicin, in Patients with Metastatic Adenocarcinoma of the Colon
J. Eckardt (1994)
Amphipathic polyethylene glycols effectively prolong the circulation time of Iiposomes
AL Klibanov (1990)
10.1016/0005-2736(93)90105-9
Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases.
G. Haran (1993)
10.1021/BI00063A030
Interbilayer transfer of phospholipid-anchored macromolecules via monomer diffusion.
J. Silvius (1993)



This paper is referenced by
10.24931/2413-9432-2018-7-4-16-22
Изучение фармакокинетики фотосенсибилизатора на основе липосомальной формы тетра-3-фенилтиофталоцианина гидроксиалюминия у мышей
А. П. Будько (2019)
10.3109/09687688.2010.507788
Light-sensitive lipid-based nanoparticles for drug delivery: design principles and future considerations for biological applications
Amichai Yavlovich (2010)
10.1016/j.jconrel.2011.04.005
Hyperthermia-triggered intracellular delivery of anticancer agent to HER2(+) cells by HER2-specific affibody (ZHER2-GS-Cys)-conjugated thermosensitive liposomes (HER2(+) affisomes).
B. Smith (2011)
10.1002/9781118229019.CH12
Immunoliposomes for Specific Drug Delivery
M. Calin (2012)
Nanoparticulate drug-delivery systems: lymphatic uptake and its gastrointestinal applications -
Saikat Ghosh (2014)
10.4155/TDE.10.86
Naposomes: a new class of peptide-derivatized, target-selective multimodal nanoparticles for imaging and therapeutic applications.
A. Accardo (2011)
Ultrasound Stimulated Release of Liposomes
M. Afadzi (2008)
10.1016/S0005-2736(02)00702-2
Design and characterization of enzymosomes with surface-exposed superoxide dismutase.
M. M. Gaspar (2003)
10.3164/JCBN.35.29
Tocopheryl Succinate-Versatile Functions due to Its Unique Physicochemical Properties
K. Kogure (2004)
Advances in Brief A New Temperature-sensitive Liposome for Use with Mild Hyperthermia : Characterization and Testing in a Human Tumor Xenograft Model 1
D. Needham (2000)
10.5772/22656
Combination Chemotherapy in Cancer: Principles, Evaluation and Drug Delivery Strategies
A. C. Pinto (2011)
10.1016/j.ultras.2016.04.007
Implementation of a PMN-PT piezocrystal-based focused array with geodesic faceted structure.
Z. Qiu (2016)
10.18388/ABP.2000_3985
Liposomal drug delivery, a novel approach: PLARosomes.
A. Kozubek (2000)
10.1023/A:1011080211226
Host Factors Influencing the Preferential Localization of Sterically Stabilized Liposomes in Klebsiella Pneumoniae-Infected Rat Lung Tissue
R. Schiffelers (2004)
10.1016/S0378-5173(01)00643-3
The combined effect of IDA and glutaraldehyde on the properties of human erythrocytes.
A. Szwarocka (2001)
10.1016/J.BBAMEM.2004.07.003
Acoustically active liposomes for drug encapsulation and ultrasound-triggered release.
S. Huang (2004)
Erkenntnisse und Ergebnisse einer prospektiven klinischen Phase II Studie zur Chemotherapie des hormonrefraktären Prostatakarzinoms mit PEG-liposomalen Doxorubicin (Caelyx R )
J. Goecke (2005)
In vivo synergistic interaction of liposome-coencapsulated gentamicin and ceftazidime.
R. Schiffelers (2001)
10.1211/0022357991773122
Preparation, Relative Toxicity and Therapeutic Efficacy in Mice and Rats of Liposomal HA‐1–92, a New Oxohexaene Polyene Macrolide Antibiotic
J. Harindran (1999)
10.1016/S0169-409X(98)00105-7
Delivery of diagnostic agents in computed tomography.
Krausé (1999)
10.1111/J.1740-8261.2000.TB01462.X
The role of liposomes in drug delivery and diagnostic imaging: a review.
M. L. Matteucci (2000)
ISSN: 0975-766X CODEN: IJPTFI Available Online through
R. Bhargavi (2011)
THERAPEUTIC INDEX OF GLUCOCORTICOIDS CAN BE OPTIMIZED BY ENCAPSULATING HIGH-CLEARANCE GLUCOCORTICOIDS IN LONG-CIRCULATING LIPOSOMES
Josbert (2003)
Pharmacological characterisation of selective Y4 and dual Y2/Y4 receptor agonists : novel targets for putative anti-obesity therapies
Simmi Jolly (2013)
Liposomes : Role of Complement and Inhibition by Soluble CR 1 and AntiC 5 a Hemoglobin in Pigs : A Model for Pseudoallergic Cardiopulmonary Reactions to Hemodynamic Changes Induced by Liposomes and Liposome-Encapsulated
D. Dobbins (1999)
10.1016/S1773-2247(13)50004-9
Magnetic-fluid-loaded liposomes for MR imaging and therapy of cancer
H. Marie (2013)
10.1046/J.1523-5394.1998.006004251.X
Liposomes as drug delivery systems.
A. P. Clark (1998)
10.1007/s00330-008-0906-0
Image-guided focused ultrasound ablation of breast cancer: current status, challenges, and future directions
A. Schmitz (2008)
10.1088/1468-6996/9/1/014109
Challenges and breakthroughs in recent research on self-assembly
K. Ariga (2008)
Nanoparticles: Advances in Drug Delivery Systems
Nishikant C. Shinde (2012)
10.1002/jps.23254
Accelerated blood clearance of pegylated liposomal topotecan: influence of polyethylene glycol grafting density and animal species.
C. Li (2012)
10.1155/2013/456409
Liposomal Doxorubicin in the Treatment of Breast Cancer Patients: A Review
J. Lao (2013)
See more
Semantic Scholar Logo Some data provided by SemanticScholar